- Home
- FIGR vs CYTK Comparison
FIGR vs CYTK Comparison
Compare FIGR & CYTK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | FIGR | CYTK |
|---|---|---|
| Founded | 2018 | 1997 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Finance: Consumer Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 6.6B | 7.6B |
| IPO Year | N/A | 2004 |
Fundamental Metrics
Financial Performance| Metric | FIGR | CYTK |
|---|---|---|
| Price | $36.24 | $59.89 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 9 | 18 |
| Target Price | $54.89 | ★ $87.56 |
| AVG Volume (30 Days) | ★ 6.0M | 1.7M |
| Earning Date | 01-01-0001 | 05-25-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $13,368,000.00 |
| Revenue This Year | $64.69 | $9.79 |
| Revenue Next Year | $20.96 | $302.66 |
| P/E Ratio | $134.36 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $25.01 | $29.31 |
| 52 Week High | $78.00 | $70.98 |
Technical Indicators
Market Signals| Indicator | FIGR | CYTK |
|---|---|---|
| Relative Strength Index (RSI) | 49.03 | 40.30 |
| Support Level | $35.28 | $59.25 |
| Resistance Level | $44.76 | $65.93 |
| Average True Range (ATR) | 3.37 | 2.65 |
| MACD | 1.57 | -0.32 |
| Stochastic Oscillator | 69.67 | 3.98 |
Price Performance
Historical ComparisonAbout FIGR Figure Technology Solutions Inc.
Figure Technology Solutions Inc is a suite of blockchain-based products and solutions centered around the vision of promoting efficiency and liquidity in financial markets. The company offers a technology-enabled loan origination system and paired this system with a distribution marketplace, Figure Connect, providing access to a deep and broad pool of capital markets partners.
About CYTK Cytokinetics Incorporated
Cytokinetics Inc is a late-stage biopharmaceutical company focused on discovering, developing and commercializing first-in-class muscle activators and next-in-class muscle inhibitors as potential treatments for debilitating diseases in which muscle performance is compromised and/or declining. The company develops treatments for diseases such as amyotrophic lateral sclerosis, heart failure, spinal muscular atrophy, and chronic obstructive pulmonary diseases. The treatment is based on small molecules specifically engineered to increase muscle function and contractility. The company is developing muscle-directed investigational medicines that may potentially improve the health span of people with devastating cardiovascular and neuromuscular diseases of impaired muscle function.